Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.
[BACKGROUND/AIM] The role of neoadjuvant chemotherapy (NAC) in treating initially resectable colorectal cancer liver metastases (CRCLM) remains controversial.
- 표본수 (n) 31
- HR 1.87
APA
Takahashi H, Kojima D, et al. (2025). Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.. Anticancer research, 45(10), 4547-4564. https://doi.org/10.21873/anticanres.17801
MLA
Takahashi H, et al.. "Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.." Anticancer research, vol. 45, no. 10, 2025, pp. 4547-4564.
PMID
41006046
Abstract
[BACKGROUND/AIM] The role of neoadjuvant chemotherapy (NAC) in treating initially resectable colorectal cancer liver metastases (CRCLM) remains controversial.
[PATIENTS AND METHODS] We retrospectively compared outcomes between patients who underwent upfront surgery and those who received NAC followed by curative CRCLM surgery. Factors associated with early relapse were also investigated. Fifty-three patients were included (upfront surgery: n=31, NAC: n=22).
[RESULTS] The 3-year overall survival (OS) and relapse-free survival (RFS) rates were comparable between the upfront surgery and NAC groups [OS: 83.9% 81.8%, =0.9, hazard ratio (HR)=1.07; RFS: 58.1% 36.4%, =0.1, HR=1.87]. However, among metachronous CRCLM cohorts, the 3-year OS rates were 88.2% and 90.0% (=0.9, HR=0.85), and the 3-year RFS rates were 76.4% and 30.0% (=0.015, HR=4.03), respectively. Patients with higher computed tomography values in CRCLM had significantly better RFS than those with lower values (=0.04). Conversely, a higher number of CRCLM after NAC was significantly correlated with shorter RFS (=0.007).
[CONCLUSION] Routine NAC for initially resectable metachronous CRCLM should be avoided because of the high risk of early relapse.
[PATIENTS AND METHODS] We retrospectively compared outcomes between patients who underwent upfront surgery and those who received NAC followed by curative CRCLM surgery. Factors associated with early relapse were also investigated. Fifty-three patients were included (upfront surgery: n=31, NAC: n=22).
[RESULTS] The 3-year overall survival (OS) and relapse-free survival (RFS) rates were comparable between the upfront surgery and NAC groups [OS: 83.9% 81.8%, =0.9, hazard ratio (HR)=1.07; RFS: 58.1% 36.4%, =0.1, HR=1.87]. However, among metachronous CRCLM cohorts, the 3-year OS rates were 88.2% and 90.0% (=0.9, HR=0.85), and the 3-year RFS rates were 76.4% and 30.0% (=0.015, HR=4.03), respectively. Patients with higher computed tomography values in CRCLM had significantly better RFS than those with lower values (=0.04). Conversely, a higher number of CRCLM after NAC was significantly correlated with shorter RFS (=0.007).
[CONCLUSION] Routine NAC for initially resectable metachronous CRCLM should be avoided because of the high risk of early relapse.
MeSH Terms
Humans; Male; Female; Colorectal Neoplasms; Liver Neoplasms; Neoadjuvant Therapy; Middle Aged; Aged; Neoplasm Recurrence, Local; Retrospective Studies; Chemotherapy, Adjuvant; Adult; Antineoplastic Combined Chemotherapy Protocols; Neoplasms, Second Primary
같은 제1저자의 인용 많은 논문 (5)
- Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
- Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
- Scrotal uptake on PSMA PET in prostate cancer: differentiating metastases from benign and physiologic findings using ultrasound correlation.
- Efficacy of CD19 CAR T-cell therapy in active vitreoretinal lymphoma.
- Intratumoral perforation following endoscopic duodenal stent placement for pancreatic cancer with gastric outlet obstruction.